Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Current Liabilities (2019 - 2026)

C4 Therapeutics has reported Total Current Liabilities over the past 8 years, most recently at $27.2 million for Q1 2026.

  • For Q1 2026, Total Current Liabilities fell 33.25% year-over-year to $27.2 million; the TTM value through Mar 2026 reached $27.2 million, down 33.25%, while the annual FY2025 figure was $33.0 million, 26.88% down from the prior year.
  • Total Current Liabilities for Q1 2026 was $27.2 million at C4 Therapeutics, down from $33.0 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $55.0 million in Q1 2024 and troughed at $27.2 million in Q1 2026.
  • A 5-year average of $42.5 million and a median of $44.5 million in 2025 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: surged 43.02% in 2024 and later plummeted 33.25% in 2026.
  • Year by year, Total Current Liabilities stood at $44.5 million in 2022, then decreased by 4.0% to $42.8 million in 2023, then grew by 5.64% to $45.2 million in 2024, then fell by 26.88% to $33.0 million in 2025, then fell by 17.51% to $27.2 million in 2026.
  • Business Quant data shows Total Current Liabilities for CCCC at $27.2 million in Q1 2026, $33.0 million in Q4 2025, and $35.9 million in Q3 2025.